Delivering a step-change in the selectivity and potency of targeted biotherapeutics
Bi-Cygni
®
Based on differentiated biology, Bi-Cygni® converts BiVictriX’s novel panel of cancer-restricted target antigen combinations into potent bispecific therapeutics with improved therapeutic index
BiVictriX's Novel Panel of Cancer-Restricted
Antigen Combinations
Bi-Cygni
Generation of leads with improved potency and selectivity
®
Lead Optimization
in to Multiple Therapeutic Modalities
BiVictriX links Bi-Cygni to expertise in the design, discovery and development of Antibody Drug Conjugates (ADCs).
®
-
Conventional Antibody Drug Conjugates (ADCs) target single antigens expressed on the tumour cell surface
-
Many of the targeted antigens are not cancer-restricted and are often widely expressed on healthy cells, resulting in debilitating on-target, off-tissue toxicities
-
BiVictriX has identified a unique, cancer-restricted antigen fingerprint, absent from healthy cells, which can be exploited to produce truly cancer selective therapeutics
-
The Bi-Cygni technology was developed to exploit this concept and expedite the development of bispecific therapeutics with improved therapeutic index
-
BiVictriX's Bi-Cygni ADCs demonstrate superior potency and tumour selectivity compared to conventional ADCs
®
®
